NUCLEOFILL™ MEDIUM PLUS
€129.00
Manufacturer: Promoitalia
Active Substance(s): POLYMERISED POLYNUCLEOTIDE
Strength: 20mg/ml
Pack Size: 1 x 2ml Pre-Filled Syringes
Nucleofill is a new line of biostimulant gel based on natural polynucleotides and high viscosity for skin rejuvenation and protection. As an anti-ageing mesotherapy treatment, Nucleofill is designed to improve skin elasticity and tightness as well as aid in the prevention of wrinkles. Rejuvenate skin around eyes.
NUCLEOFILL™ MEDIUM PLUS Product Summary
NUCLEOFILL™ MEDIUM PLUS is a cutting-edge bio-restructuring injectable gel designed for skin revitalization and repair. It features natural polynucleotides formulated for deeper hydration, anti-aging effects, and tissue regeneration. This advanced product targets oxidative stress and signs of aging, delivering significant improvements in skin elasticity and tone.
- Type: Polynucleotide-based bio-stimulant gel.
- Intended Use: Facial and body skin rejuvenation.
- Packaging: Supplied in sterile, pre-filled syringes.
NUCLEOFILL™ MEDIUM PLUS Key Features and Benefits
This product offers comprehensive skin enhancement through hydration, regeneration, and protection.
- Hydration: Deep and prolonged water-binding capability enhances skin moisture levels.
- Antioxidant Properties: Neutralizes free radicals, reducing oxidative stress.
- Fibroblast Stimulation: Increases collagen and elastin production for improved dermal structure.
- Regenerative Action: Promotes cellular renewal and tissue repair.
- Elasticity Restoration: Provides a subtle lifting effect by activating myofibroblasts.
NUCLEOFILL™ MEDIUM PLUS Composition
NUCLEOFILL™ MEDIUM PLUS uses high-purity ingredients optimized for maximum efficacy.
- Polynucleotide Concentration: 2.5%.
- Molecular Weight: 2,500 kDa for effective dermal bioavailability.
- Viscosity: 48–65 Pa*s, ensuring precise application and integration into tissues.
NUCLEOFILL™ MEDIUM PLUS Intended Purpose / Indications
This product is suitable for a wide range of skin rejuvenation applications.
- Indications:
- Severe wrinkles and sagging skin.
- Skin damaged by oxidative stress.
- Atrophic scars, including acne scars.
- Targeted Treatment Areas:
- Face: Cheeks, nasolabial folds, and jawline.
- Body: Décolleté, neck, and hands.
NUCLEOFILL™ MEDIUM PLUS Injection and Treatment Areas
It is formulated for deep and targeted rejuvenation, suitable for various treatment zones.
- Recommended Injection Areas:
- Facial zones like periorbital regions and jawline.
- Neck and chest for elasticity improvements.
- Hands for volume and texture restoration.
- Injection Depth: Delivered into the dermis or subcutaneous layers, depending on the treatment objective.
NUCLEOFILL™ MEDIUM PLUS Reconstitution and Preparation Guidelines
The product comes pre-filled and requires no additional preparation, ensuring convenience and sterility.
- Preparation Guidelines:
- Open the sterile packaging in an aseptic environment.
- Attach the included 30G needle securely to the syringe.
- Inspect the solution to ensure no particulates are present before injection.
NUCLEOFILL™ MEDIUM PLUS Administration and Dosage
Proper administration is crucial for achieving optimal results while minimizing risks.
- Injection Techniques:
- Use multi-puncture or linear threading methods based on the area.
- Deliver approximately 0.1 mL per point at intervals of 1 cm.
- Dosage:
- A typical session requires 1.5 mL per area, depending on the extent of treatment.
- Initial treatments involve 3 sessions spaced 15–30 days apart.
NUCLEOFILL™ MEDIUM PLUS Storage Instructions
Correct storage ensures the product’s efficacy and safety.
- Store at 2–30°C in a dry, light-protected environment.
- Avoid freezing and ensure the package remains sealed until use.
- Always verify the expiration date before administration.
NUCLEOFILL™ MEDIUM PLUS Contraindications
Specific conditions must be considered to avoid adverse effects.
- Not Suitable For:
- Patients allergic to polynucleotides or related components.
- Areas with active infections or inflammation.
- Pregnant or breastfeeding individuals.
- Patients with autoimmune disorders or severe chronic illnesses.
NUCLEOFILL™ MEDIUM PLUS Precautions and Warnings
Strict adherence to safety precautions ensures successful outcomes.
- Avoid injecting near blood vessels to minimize risks of intravascular complications.
- Do not mix with other injectables or undergo simultaneous aesthetic procedures.
- Thorough patient consultation is necessary to assess suitability and risks.
NUCLEOFILL™ MEDIUM PLUS Post-Treatment Care
Post-treatment guidelines promote optimal healing and results.
- Care Instructions:
- Avoid UV exposure, extreme temperatures, and physical exertion for 48 hours.
- Use soothing, non-comedogenic skincare products.
- Apply SPF 50 sunscreen daily to protect treated areas.
NUCLEOFILL™ MEDIUM PLUS Side Effects and Adverse Reactions
The product is well-tolerated, with minimal side effects reported.
- Common Side Effects:
- Redness, mild swelling, and tenderness at injection sites.
- Temporary bruising or itching.
- Rare Reactions:
- Formation of small nodules or discoloration that resolve with time.
NUCLEOFILL™ MEDIUM PLUS Patient Eligibility
This product is suitable for adults seeking comprehensive skin rejuvenation.
- Ideal Candidates:
- Adults with moderate to severe skin aging or oxidative damage.
- Those seeking non-invasive solutions for volume and elasticity improvement.
- Not recommended for individuals under 18 years or with unrealistic expectations.
NUCLEOFILL™ MEDIUM PLUS Follow-Up and Maintenance
A consistent treatment protocol ensures sustained and enhanced results.
- Follow-Up Schedule:
- Initial treatment series of 3 sessions every 2–4 weeks.
- Maintenance sessions every 4–6 months, depending on patient needs.
NUCLEOFILL™ MEDIUM PLUS Manufacturer and Regulatory Information
NUCLEOFILL™ MEDIUM PLUS is produced by Biosimil Aesthetics, a leader in polynucleotide-based solutions.
- Manufacturer: Biosimil Aesthetics.
- Certifications: CE-marked for safety and efficacy in skin rejuvenation.

Reviews
There are no reviews yet.